ReviewJournal of mammary gland biology and neoplasia2008
Amphiregulin as a novel target for breast cancer therapy.
Review in Journal of mammary gland biology and neoplasia, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 52 citations in OpenAlex.
- Comparative study and meta-analysis of meta-analysis studies for the correlation of genomic markers with early cancer detection.Human genomics · 2013Pooled it
- Multi-omics analysis to uncover the molecular basis of tumor budding in head and neck squamous cell carcinoma.NPJ precision oncology · 2025Article
- Triiodothyronine (T3) increases the expression of the amphiregulin (AREG) oncogene by activating extranuclear pathways in MCF-7 breast cancer cells.Archives of endocrinology and metabolism · 2024Article
- Reciprocal fine-tuning of progesterone and prolactin-regulated gene expression in breast cancer cells.Molecular and cellular endocrinology · 2020Article
- Transcription-independent Induction of ERBB1 through Hypoxia-inducible Factor 2A Provides Cardioprotection during Ischemia and Reperfusion.Anesthesiology · 2020Article
- Triiodothyronine Promotes Cell Proliferation of Breast Cancer via Modulating miR-204/Amphiregulin.Pathology oncology research : POR · 2019Article
- Co-administering Melatonin With an Estradiol-Progesterone Menopausal Hormone Therapy Represses Mammary Cancer Development in a Mouse Model of HER2-Positive Breast Cancer.Frontiers in oncology · 2019Article
- EGFR is required for FOS-dependent bone tumor development via RSK2/CREB signaling.EMBO molecular medicine · 2018Article
- Loss of amphiregulin reduces myoepithelial cell coverage of mammary ducts and alters breast tumor growth.Breast cancer research : BCR · 2018Article
- Human chorionic gonadotropin promotes cell proliferation through the activation of c-Met in gastric cancer cells.Oncology letters · 2018Article
- CRB3 and the FERM protein EPB41L4B regulate proliferation of mammary epithelial cells through the release of amphiregulin.PloS one · 2018Article
- Amphiregulin as a Novel Serum Marker of Puberty in Girls.Journal of pediatric and adolescent gynecology · 2017Article
- Article
- G-protein-coupled receptor 81 promotes a malignant phenotype in breast cancer through angiogenic factor secretion.Oncotarget · 2016Article
- Effects of the lifestyle habits in breast cancer transcriptional regulation.Cancer cell international · 2016Review
- Amphiregulin enhances intercellular adhesion molecule-1 expression and promotes tumor metastasis in human osteosarcoma.Oncotarget · 2015Article
- MiR-34a suppresses amphiregulin and tumor metastatic potential of head and neck squamous cell carcinoma (HNSCC).Oncotarget · 2015Article
- Estrogen-responsive genes overlap with triiodothyronine-responsive genes in a breast carcinoma cell line.TheScientificWorldJournal · 2014Article
- Cyclin D1 determines estrogen signaling in the mammary gland in vivo.Molecular endocrinology (Baltimore, Md.) · 2013Article
- Niche-modulated and niche-modulating genes in bone marrow cells.Blood cancer journal · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Amphiregulin, an EGF family growth factor, binds and activates the epidermal growth factor receptor (EGFR or ErbB1). Activation of the EGFR by amphiregulin can occur through autocrine, paracrine and juxtacrine mechanisms. Amphiregulin plays a role in several biological processes including nerve regeneration, blastocyst implantation, and bone formation. Amphiregulin also plays an important role in mammary duct formation as well as the outgrowth and branching of several other human tissues such as the lung, kidney and prostate. This effect is most likely due to the induction of genes involved in invasion and migration such as cytokines and matrix metalloproteases. Clinical studies have suggested that amphiregulin also plays a role in human breast cancer progression and its expression has been associated with aggressive disease. Therefore, amphiregulin may be a novel and effective target for the treatment of breast cancer and could represent an alternative to targeting the EGFR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.